Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

7 companies in the race to make an artificial pancreas

March 31, 2017 By Fink Densford

Beta Bionics: A little fish looking to make big waves

One of the newest players to the race, startup Beta Bionics, is leveraging technology licensed from Boston University to develop the iLet bionic pancreas. Beta Bionics is actually a Massachusetts public benefit corporation; Boston University biomedical engineering professor Ed Damiano initially designed the iLet so that his son could have a bionic pancreas to take with him to college. 

The bionic pancreas is wirelessly connected to its 2 pumps using a smartphone, which receives a reading every 5 minutes from a continuous glucose monitor. The algorithms controlling the system calculate a dose of either insulin or glucagon depending on the patient’s blood glucose level.

The device will also deliver anticipatory insulin doses if patients enter information about an upcoming meal. The system is designed to control blood sugar using insulin and a hormone that increases glucose levels, called glucagon.

The technology behind Beta Bionic’s artificial pancreas was able to outperform conventional insulin pump therapy, according to a study from the Massachusetts General Hospital which was published in The Lancet late last year.

The study included 39 adults with type 1 diabetes who had used an insulin pump to manage their diabetes for at least 6 months prior to the start of the trial. All participants used the bionic pancreas for 11 days and their usual insulin pump for the other 11-day study period.

When participants were using the bionic pancreas, their average blood glucose levels were 141 mg/dl compared to 162 mg/dl while undergoing standard treatment. Patients also experienced less hypoglycemia while sleeping using the bionic pancreas compared to their standard regimen.

Next>

Pages: 1 2 3 4 5 6 7 8 9

Comments

  1. Gayle Kirma says

    April 3, 2017 at 7:49 pm

    I’m patiently waiting for this to hit the marke; T1 for 58 years!

    Thank you!

    • Chris Newmarker says

      April 4, 2017 at 4:30 pm

      Thanks for the comment, Gayle. Hope you don’t have to wait much longer!

  2. James Dunlop says

    April 5, 2017 at 5:47 am

    but what about the advancements in this? worth looking at, it is being investigated by the same people that are investing in this product. hope for us T1 diabetics is coming, one way or another. there is hope.

    http://thejdca.org/practical-cure-project-update-bcg

  3. Erika Payne says

    April 5, 2017 at 12:43 pm

    Hats off to you, Gayle.

    Waiting impatiently.

    Mum of a 10-year-old T1

  4. Debbie says

    April 5, 2017 at 8:01 pm

    How do i get to be in the trial?

  5. Ronnie McBride says

    April 5, 2017 at 11:58 pm

    This will be great. I am 67 years old and am fighting the battle of diabetes. I would love to trial test something like this. I worked in the Medical field for 39 years and was always studying how to beat this terrible disease.

    Ronnie McBride

  6. James Culp says

    April 6, 2017 at 12:12 am

    I wish all success. I hope for biological approach to protect islet insulin producing cells for implant or infusion of cells to restore natural function of glucose metabolism. May God help us.

  7. Pat McAlister says

    June 3, 2017 at 4:59 pm

    T1D for 70 years. Why not a cure instead of costing us more and more to live. We are the support of these drug and device companies. Thank you for this article. I do a diabetic newsletter for a T1D optimist club. Our next speaker is building his own device.

    • Chris Newmarker says

      June 5, 2017 at 6:20 pm

      Thanks for the insights, Pat. I think it really says something about the motivation of the diabetes community that there’s so much do-it-yourself activity going on with devices, including when it comes to an artificial pancreas. Who do you have speaking?

  8. Frank van Olffen says

    May 12, 2018 at 10:06 pm

    You forgetting a big player in the Netherlands.

    https://inredadiabetic.nl

    • Chris Newmarker says

      May 16, 2018 at 4:33 pm

      Thanks for pointing out, Frank!

Related Articles Read More >

A portrait of Ellen Roche, MIT School of Engineering associate professor
New implant design prevents scar tissue without drugs, MIT says
CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
A portrait of Dexcom VP of Global Clinical Initiatives Tomas Walker
Dexcom focuses on early diabetes diagnosis as COVID links emerge
A portrait of Proximie CEO Nadine Hachach-Haram
They said it at DeviceTalks Boston

DeviceTalks Weekly.

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech